Glatter: In practice, many patients labeled non-responders to GLP-1 therapy are experiencing incomplete dosing, early discontinuation because of gastrointestinal side effects, insufficient treatment duration, or competing metabolic drivers such as severe insulin resistance, sleep disruption, sarcopenia, or medication-associated weight gain
The American College of Obstetricians and Gynecologists recommends discontinuing GLP-1 medications three months before attempting conception, though individual timelines depend on your health profile and treatment goals
The present study aimed to investigate the potential protective effect of vitamin E on salivary glands, with a specific focus on enhancing parotid excretion function
Clinicians must also navigate how best to incorporate these agents into existing treatment algorithms, particularly in patients with overlapping systemic disease or partial response to traditional immunosuppressants
Intestinal Barrier Function: Molecular Regulation and Disease Pathogenesis